Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs' Board approved several items including the 30th AGM notice and Annual Report for FY 2024–25, scheduled for 30 September 2025, with book closure from 24 to 30 September 2025. It approved the audited standalone and consolidated financial statements for the year ending 31 March 2025. The Board re-appointed Mr. S. Nagi Reddy as Chairman and Managing Director for 4 years starting 30 May 2026, and re-appointed Mr. S. Koni Reddy and Mr. S. Manoj Kumar Reddy as Whole-Time Directors for 5 years. Mr. Satyam Reddy Gopidi was appointed as a new Independent Director for a 5-year term, and PSK & Associates was appointed as Secretarial Auditor for 5 years (FY 2025–26 to FY 2029–30). The Board also sought shareholder approval for material related party transactions for FY 2025–26 and ratified the remuneration of cost auditor KJU & Associates.
This is largely a routine governance and AGM-preparation filing. Shareholders should note the book closure period (24–30 September 2025) and 23 September 2025 cut-off date for e-voting eligibility. The re-appointments of the promoter family (Nagi Reddy and his two sons) maintain existing management control, while several items require shareholder approval at the upcoming AGM.